HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume  

 

 

If you want to download the journal, please login or register as reader.

2021 Issues

Cover

Vol. 23 • Na. N1 • February 2021

In this issue:

  • Impact of Health Education on the Treatment of Hepatitis C Infection in Patients in Drug Addiction Treatment Centres in Serbia
    Jovanovic M., Todorov N., Dickov A., Arsenijevic V., Kovacevic M., Mijailovic Z., and Colovic S.
  • Subjective Opiate Withdrawal Scale and Toxicological Screening in Malaysian Opioid Drug Addicts
    Wiraagni I.A., Mohd M.A., Rashid R.b.A., and Haron D.E.b.M.
  • Self Efficacy and Quality of Life of Participants Undergoing Treatment for Drug Addiction in Pakistan
    Ishrat S., Naz S., Gul I., and Sireer N.
  • Opioid Agonist Treatment for Opioid Use Disorder Patients in Central Asia
    Michels I.I., Stöver H., Aizberg O., and Boltaev A.
  • A Shared Medical Appointment (Sma) Model for U.S. Veterans Treated with Buprenorphine in an Outpatient Setting: an Appraisal of Mortality, Risk, and Protective Factors
    Phelan J.E.
  • Risk of Sleep Disordered Breathing and Treatment Dilemma While on Methadone Maintenance Treatment in Opioid Use Disorder Patients
    Riaz U.
  • The ‘Prison Zero Hepatitits' Project in France: A New Pathway for Hcv Microelimination
    Remy A.-J., Roy B., and Hervet J.
  • Switching All Patients from Racemic to Levomethadone as a Challenge to Public Health
    Deruvo G., Elia C., Mercadante M., Mongiello F., Guareschi M., and Maremmani I.
  • Psychopathological Syndromes and Risk of Alcoholism in Heroin Use Disorder Patients Compared with Substance Non-User Peers
    Miccoli M., Della Rocca F., Maremmani A.G.I., and Maremmani I.
  • The Complexities of Monitoring and Responding to Illegal Ghb Use and Overdose - Are We Sufficiently Equipped?
    Crowley D., and Van Hout M.C.

 

Cover

Vol. 23 • Na. N2 • April 2021

In this issue:

  • Outcomes for Patients Receiving Telemedicine-Delivered Medication-Based Treatment for Opioid Use Disorder: A Retrospective Chart Review
    Weintraub E., Greenblatt A.D., Chang J., Welsh C.J., Berthiaume A.P., Goodwin S.R., Arnold R., Himelhoch S.S., Bennett M.E., and Belcher A.M.
  • Effectiveness of Medication-Assisted Therapy in Malaysia. A Systematic Review and Meta-Analysis after a Decade.
    Musa R., and Yee A.
  • Agonist Opioid Treatment for Opioid Dependents in Germany 2019
    Stöver H., Michels I.I., and Gerlach R.
  • How to Improve a Poorly Running Agonist Opioid Treatment (Aot). Part 7: Overcoming the Alcohol Dependence of Methadone Patients
    Ulmer A., Frietsch B., and Mueller M.
  • Obsessive Compulsive Disorder among Patients Enrolled in Methadone Maintenance Therapy
    Kheradmand A., Khalatabadi P., and Seif P.
  • Rehabilitation of Patients Dependent on New Psychoactive Substances in Russian Federation
    Kekelidze Z.I., Kozlov A.A., Klimenko T.V., Igumnov S.A., and Shakhova S.M.
  • Further Evidence of a Psychopathology Specific to Substance Use Disorder. Relationships between Psychopathological Dimensions and Alcohol Craving in Recreational Drinkers
    Miccoli M., Poli A., Pagni L., Conversano C., Pani P.P., Maremmani A.G.I., and Maremmani I.
  • Effectiveness of Deep Brain Stimulation in Treatment of Severe Addiction
    Famitafreshi H., and Karimian M.

 

Cover

Vol. 23 • Na. N3 • June 2021

In this issue:

  • Drugs as communication between ego and self. Revisiting C.G. Jung
    Leoncini T., and Maremmani I.
  • The relationship of alexithymia with difficulty in emotional regulation, anxiety, and depression symptoms in a group of patients receiving opioid maintenance treatment
    Karabulut V., Evren C., Alniak İ., Helin Carkcı O., and Yilmaz Cengel H.
  • Follow-up of serum naltrexone levels after naltrexone implant in opioid use disorder
    Kulaksızoğlu B., Erdoğan A., Cinemre B., Topcuoğlu M., Coşkun M.N., Özdemir M., Bingöl M.S., and Kuloğlu M.M.
  • Somatic diseases in patients with opioid use disorder
    Simonovska N., Velik-Stefanovska V., Babulovska A., Pereska Z., Kostadinoski K., and Naumoski K.
  • Patterns of pain killers and other opioid use in patients admitted to a detoxification and dual diagnosis unit, 2016-19: a retrospective cohort study
    Casado-Espada N.M., Alvarez-Navares A., Lozano-Lopez M.T., Gamonal-Limcaoco R.S., de la Iglesia-Larrad J., Garzón M.Á., Dening T., and Roncero C.
  • Take-home naloxone carriage among opioid users in Lanarkshire
    Hill D.R., Al Azizi B., Conroy S., and Akram G.
  • How supportive and understandable are health care practitioners toward people who use drugs in Albania?
    Tivari Bitri S., Puca E., Thoma E., and Sotiri E.
  • Covid-19 and addiction: A comparison between Substance Use Disorder patients and gamblers
    Incerti C.C., Carenti M.L., Catalano G., De Luca O., Arcangeli N., Manasse D., and Casella P.
  • Exploring the Depressive Syndrome of Heroin Use Disorder patients. Relationships between Worthlessness/Being Trapped, Deficit Reward and Post-Withdrawal Syndromes
    Della Rocca F., Novi M., Maremmani A.G.I., Pani P.P., Miccoli M., and Maremmani I.
  • Caring for opioid drug users during the COVID-19 pandemic – a commentary on the Irish experience
    Crowley D., and Cullen W.
  • Despite Repeated Criticism, Medications (Methadone, Suboxone) For Opioid Use Disorder Continue Being Called "Substitution" Treatments
    Appel P.

 

Cover

Vol. 23 • Na. N4 • August 2021

In this issue:

  • The effect of cognitive behaviour group therapy on drug dependence among heroin addicts in Taiwan: What roles do drug beliefs, drug craving, and intention to relapse play?
    Lin M.-F., and Lang S.-Y.
  • Effect of methadone and treadmill exercise on myocardial infarction in morphine withdrawn rats
    Alizadeh M., Miladi-Gorji H., Sameni H., Bandegi A., Ebadatipour E., and Zahedi-Khorasani M.
  • Traditional Chinese Medicine-Based Medication-Assisted Therapy for Switching from Methadone to Buprenorphine/Naloxone in treating Opioid Use Disorder
    Yu K.-C., Wei H.-T., Chih S.-Z., and Hsu C.-H.
  • Effectiveness, tolerability and safety of a long-term therapy with levomethadone in clinical practice: a retrospective observational study
    Consoli A.
  • Naltrexone Implant Use in Opioid Use Disorder; an example from Turkey
    Demir B., and Altindag A.
  • An Assertive Outreach Intervention for Treatment of Opioid Use Disorder in Young Adults
    Wenzel K., Fishman M., Wildberger J., Vo H., and Burgower R.
  • Methadone intoxications and methadone-related deaths during a five-year period in Vojvodina, Serbia
    Nosek I.P., Dušan, Mijatović Jovin V., Samojlik I., Petković S.D., Zorka Knezovic, Vladimir, and Dickov A.
  • Early-readmission after Agonist Opioid Treatment in five European countries. A drug addiction health policy challenge?
    Maremmani I., Hill D., Scherbaum N., Auriacombe M., Bacciardi S., Benyamina A., Casella P., D'Agnone O., Daulouede J.-P., Deruvo G., Fonseca F., Guareschi M., Maremmani A.G.I., Villeger P., Ratcliffe K., Somaini L., Touzeau D., Vernole E., Walcher S., and

 

Cover

Vol. 23 • Na. N5 • October 2021

In this issue:

  • Comparison of Impulsivity with Self-Report and Behavioral Method in Patients with Opioid Use Disorder
    Barlas L., Ünübol B., and Dağ İ.
  • Reducing Opioid Dependence Therapy risk in the prison system and the use of extended-release buprenorphine as an additional treatment option: a consensus statement
    Gross G., Conroy S., Leonardi C., Meroueh F., Antolin J.M., and Somaini L.
  • RBP-6000: a rationally designed prolonged-release buprenorphine formulation
    Wiest K., Shaya G., Somaini L., and Greenwald M.
  • A qualitative study of physical activity and dietary practices of people accessing opioid agonist treatment in Ireland
    Matthews E., Van Hout M.C., Scheibein F., and Cowman M.
  • Berberis integerrima and berberine attenuate morphine reward memory and restore the reduction of CSF serotonin levels following morphine conditioned place preference in rats
    Sabeghi S., Zahedi-Khorasani M., Ghanbari A., Khaleghian A., Doroodi F., and Miladi-Gorji H.
  • Microdosing Case Study Series – Transferring from Methadone to Oral Buprenorphine
    Cassells N., Hill D.R., Marr E., and Stewart E.
  • What makes a co-dependent partner? - A linear regression model
    Knapek É., Balázs K., and Kuritárné Szabó I.
  • Convergent validity of five-dimension psychopathology of Addiction: relationships with aggressive behaviour
    Maremmani A.G.I., Della Rocca F., Bacciardi S., Miccoli M., and Maremmani I.

 

Cover

Vol. 23 • Na. N6 • December 2021

In this issue:

  • Involuntary Commitment for Opioid Use Disorders: Is There Any Predictor of Recommitments?
    Ak S., and Arikan R.
  • The neurophysiological correlates of cognitive functions during methadone and buprenorphine maintenance treatment: The erp study
    Markovska-Simoska S., Ignjatova L., Kiteva-Trenchevska G., and Pop-Jordanova N.
  • Levels of leptin and adiponectin after initiation of methadone maintenance treatment: A systematic review and meta-analysis
    Jangipour Afshar P., Salehinejad S., and Shahesmaeili A.
  • Overdose Risk and Attitudes to Take-Home Naloxone Among Opioid Users in Prague and London: A Survey Comparison
    Sefranek M., McDonald R., Kelleher M., Breidahl S., Pavlidis P., Miovsky M., and Strang J.
  • Different formulations of methadone and levomethadone in the management of Opioid Use Disorder.
    Somaini L., Vecchio S., Salvatore D.F., Ercolini A., and Leonardi C.
  • Buprenorphine for opioid withdrawal syndrome management: comparison of different dose tapering protocols
    Stella L., D'Ambra C., Di Donato L., Infantino R., Boccella S., Mirto B.F., Luongo L., Miele M., Pieretti G., Maione S., and Guida F.
  • Convergent validity of five-dimension psychopathology of Addiction: Relationships with Tridimensional Personality Questionnaire
    Maremmani A.G.I., Della Rocca F., Bacciardi S., Miccoli M., and Maremmani I.

 

 

EUROPAD - European Opiate Addiction Treatment Association
Brussels, Belgium, EU
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page